BRANDO, Chiara
BRANDO, Chiara
Discipline Chirurgiche, Oncologiche e Stomatologiche
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming
2020-01-01 Incorvaia L.; Fanale D.; Badalamenti G.; Brando C.; Bono M.; De Luca I.; Algeri L.; Bonasera A.; Corsini L.R.; Scurria S.; Iovanna J.L.; Russo A.; Bazan V.
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
2020-01-01 Incorvaia L.; Fanale D.; Badalamenti G.; Porta C.; Olive D.; De Luca I.; Brando C.; Rizzo M.; Messina C.; Rediti M.; Russo A.; Bazan V.; Iovanna J.L.
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients
2020-01-01 Incorvaia L.; Fanale D.; Bono M.; Calo V.; Fiorino A.; Brando C.; Corsini L.R.; Cutaia S.; Cancelliere D.; Pivetti A.; Filorizzo C.; La Mantia M.; Barraco N.; Cusenza S.; Badalamenti G.; Russo A.; Bazan V.
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning
2022-05-01 Fanale D.; Pivetti A.; Cancelliere D.; Spera A.; Bono M.; Fiorino A.; Pedone E.; Barraco N.; Brando C.; Perez A.; Guarneri M.F.; Russo T.D.B.; Vieni S.; Guarneri G.; Russo A.; Bazan V.
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
2022-01-13 Fanale D.; Corsini L.R.; Scalia R.; Brando C.; Cucinella A.; Madonia G.; Dimino A.; Filorizzo C.; Barraco N.; Bono M.; Fiorino A.; Magrin L.; Sciacchitano R.; Perez A.; Russo T.D.B.; Pantuso G.; Russo A.; Bazan V.
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors
2021-01-01 Incorvaia L.; Madonia G.; Corsini L.R.; Cucinella A.; Brando C.; Gagliardo C.; Santoni M.; Fanale D.; Inno A.; Fazio I.; Foti G.; Galia M.; Badalamenti G.; Bazan V.; Russo A.; Gori S.
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
2020-01-01 Fanale, Daniele; Incorvaia, Lorena; Filorizzo, Clarissa; Bono, Marco; Fiorino, Alessia; Calò, Valentina; Brando, Chiara; Corsini, Lidia Rita; Barraco, Nadia; Badalamenti, Giuseppe; Russo, Antonio; Bazan, Viviana
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge
2021-08-01 Bono M.; Fanale D.; Incorvaia L.; Cancelliere D.; Fiorino A.; Calo V.; Dimino A.; Filorizzo C.; Corsini L.R.; Brando C.; Madonia G.; Cucinella A.; Scalia R.; Barraco N.; Guadagni F.; Pedone E.; Badalamenti G.; Russo A.; Bazan V.
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength
2022-02-09 Fanale D.; Corsini L.R.; Brando C.; Dimino A.; Filorizzo C.; Magrin L.; Sciacchitano R.; Fiorino A.; Bazan Russo T.D.; Calo V.; Iovanna J.L.; Francini E.; Russo A.; Bazan V.
MUTYH-associated tumor syndrome: The other face of MAP
2022-04-14 Magrin L.; Fanale D.; Brando C.; Corsini L.R.; Randazzo U.; Di Piazza M.; Gurrera V.; Pedone E.; Bazan Russo T.D.; Vieni S.; Pantuso G.; Russo A.; Bazan V.
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)
2021-01-01 Incorvaia L.; Badalamenti G.; Fanale D.; Vincenzi B.; Luca I.D.; Algeri L.; Barraco N.; Brando C.; Bonasera A.; Bono M.; Castiglia M.; Cancelliere D.; Cani M.; Rita Corsini L.; Fiorino A.; Galvano A.; Pedone E.; Perez A.; Pivetti A.; Graceffa G.; Pantuso G.; Cabibi D.; Russo A.; Bazan V.
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes
2021-01-01 Magrin L.; Fanale D.; Brando C.; Fiorino A.; Corsini L.R.; Sciacchitano R.; Filorizzo C.; Dimino A.; Russo A.; Bazan V.
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
2021-06-11 Fanale D.; Fiorino A.; Incorvaia L.; Dimino A.; Filorizzo C.; Bono M.; Cancelliere D.; Calo V.; Brando C.; Corsini L.R.; Sciacchitano R.; Magrin L.; Pivetti A.; Pedone E.; Madonia G.; Cucinella A.; Badalamenti G.; Russo A.; Bazan V.
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival?
2021-01-01 Fanale D.; Incorvaia L.; Badalamenti G.; De Luca I.; Algeri L.; Bonasera A.; Corsini L.R.; Brando C.; Russo A.; Iovanna J.L.; Bazan V.
Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology
2021-03-01 Manno G.; Filorizzo C.; Fanale D.; Brando C.; Di Lisi D.; Lunetta M.; Bazan V.; Russo A.; Novo G.